The Pharma Data

AUGUST 19, 2021

The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. 4,5,6 PD-1 inhibitors can be effective in cancers with MMR deficiency.

FDA Approval 52

FDA Approval DNA Reagent Protein 52

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

JANUARY 31, 2021

Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Life Science 52

Life Science Genome Genomics Reagent 52

Drug Discovery World

MAY 7, 2024

DC: Antibodies have and remain a large product class within the biopharmaceutical market. AEX chromatography has primarily been used in the polishing AEX step for the removal of impurities, such as DNA, HCP, etc., RA: In recent years, what improvements have we seen to cell-line engineering for antibodies?

Antibody 59

Antibody Production Manufacturing Engineer 59

The Pharma Data

JANUARY 31, 2021

NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. 1, 2021 00:00 UTC.

Genome 52

Genome Genomics Life Science DNA 52

Drug Discovery World

MAY 16, 2023

What opportunities and challenges are emerging and can therapies get to market faster? Moreover, he says that global supply chain pressures will continue into 2023, combined with instability in the financial markets that will make cost of goods high on his watchlist of risks to manage. DDW’s Megan Thomas finds out.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

pharmaphorum

JUNE 1, 2021

The widespread use of pill presses by criminal gangs means that they can change production and ingredients rapidly to satisfy market demand. Two different types of microtaggants are now available, one produced from non-biologic DNA and the other from silica: DNA microtaggants. Silica microtaggants.

Medicine 52

Medicine DNA Pharmacy Production 52

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). billion by 2030 (BioSpace, 11 August 2022). billion by 2030 (BioSpace, 11 August 2022).

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Cell culture challenges The viral vectors used in the gene therapies currently on the market are produced in adherent human embryonic HEK-293 cell culture. The established method for this process is a triple transfection using three different DNA plasmids. For example, researchers have developed a two-plasmid cotransfection system.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

NOVEMBER 2, 2023

The effect of several variables on the IVT reaction using different size DNA templates was assessed. Expert Dr Darwin Asa, Market Development Manager, Thermo Fisher Scientific, will present this event which will take place on 9 November, 4PM GMT, 5PM CET, 11AM EST, 8AM PST.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 23, 2023

The effect of several variables on the IVT reaction using different size DNA templates was assessed. Expert Dr Darwin Asa, Market Development Manager, Thermo Fisher Scientific, will present this event which will take place on 9 November, 4PM GMT, 5PM CET, 11AM EST, 8AM PST.

Production 52

Production In-Vitro Reagent DNA 52

Drug Discovery World

OCTOBER 16, 2023

The effect of several variables on the IVT reaction using different size DNA templates was assessed. Expert Dr Darwin Asa, Market Development Manager, Thermo Fisher Scientific, will present this event whichwill take place on 9 November, 4PM GMT, 5PM CET, 11AM EST, 8AM PST.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 9, 2023

The effect of several variables on the IVT reaction using different size DNA templates was assessed. Expert Dr Darwin Asa, Market Development Manager, Thermo Fisher Scientific, will present this event whichwill take place on 9 November, 4PM GMT, 5PM CET, 11AM EST, 8AM PST.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 2, 2023

The effect of several variables on the IVT reaction using different size DNA templates was assessed. Expert Dr Darwin Asa, Market Development Manager, Thermo Fisher Scientific, will present this event whichwill take place on 9 November, 4PM GMT, 5PM CET, 11AM EST, 8AM PST.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Depending on regional marketing authorization, TAKHZYRO is available as a 300 mg dose in a vial or pre-filled syringe. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. Likely Growth of the Spatial Omics Solutions Market. Our Social Media Platform.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. eTheRNA’s global programs will benefit from China Grand Pharma’s development, clinical and marketing input.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

OCTOBER 21, 2022

Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . Reagents produced under ISO certification provide an extra level of traceability to support internal documentation and quality assurance.

Reagent 52

Reagent Antibody Drugs Protein 52

Drug Discovery World

NOVEMBER 30, 2023

coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. The Absolute Antibody team was available to discuss custom services, as well as the company’s comprehensive antibody reagent catalogue.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

FEBRUARY 27, 2023

By focusing on workflow simplification and expanded assay capabilities in a state-of-the-art microplate reader, complemented by our optimised reagent technologies, our team has created an all-around high-performing system built for today and the future.” This collaboration provides the customisability and ability that customers seek.”

Drugs 52

Drugs Life Science Protein Scientist 52

The Pharma Data

OCTOBER 14, 2020

Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. The funds will be used to bring Ori’s innovative manufacturing platform to the market. ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52